On Thursday, Shares of General Motors Company (NYSE:GM), subtract-0.54% and closed at $31.51 in the last trading session. The last trading range of the stock ranges between $30.88 and $31.63. The company’s Market capitalization is $48.89 Billion with the total Outstanding Shares of 1.56billion. General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. The company operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. It markets its vehicles mainly under the Buick, Cadillac, Chevrolet, GMC, Opel, Holden, Vauxhall, Baojun, Jiefang, and Wuling brand names. The company also sells cars and trucks to dealers for consumer retail sales, in addition to to fleet customers, counting daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers connected safety, security and mobility solutions, and information technology services. The company, through its partner, General Motors Financial Company, Inc., provides automotive financing services.
TG Therapeutics Inc (NASDAQ:TGTX), jumped -16.97% and closed at $6.85 in the last trading session. The last trading range of the stock ranges between $6.70 and $7.33. The company’s Market capitalization is $346.17Million with the total outstanding Shares of 54.46million. TG Therapeutics, Inc. (TGTX) today announced that it has filed with the FDA an amended protocol for the GENUINE Phase 3 trial. Prior to the amendments, the GENUINE study consisted of two parts:
Part I to evaluate the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately the first 200 patients enrolled, to support a filing for accelerated approval of TG-1101; and
Part II to evaluate the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients (approximately 330), to support a filing for full approval of TG-1101.
The amended protocol contains the following substantive changes:
Part II of the study has been eliminated, and accordingly, the study’s sole primary endpoint will be ORR as originally contemplated in Part I; and
Target enrollment has been reduced to approximately 120 randomized patients.
At the new study size, the study is 90% powered to show a statistically significant improvement in ORR, with the minimal detectable difference of approximately 20% (absolute difference between the arms). Additionally, patients will be followed until progression, but the study will no longer be powered for PFS.
Community Health Systems (NYSE:CYH), gained 0.57% and closed at $10.53 in the last trading session. The last trading range of the stock ranges between $10.28 and $10.70. The company’s Market capitalization is $1.22 Billion with the total outstanding Shares of 113.64 million. During the 52-week trading session the minimum price at which share price traded, registered at $9.66 and reached to max level of $35.42. Quorum owns and operates 38 hospitals and related outpatient service centers in 16 states. Effective April 29, 2016, CHS (CYH) accomplished a spin-off of Quorum, with CHS shareholders receiving one share of Quorum common stock for every four shares of CHS stock they owned as of April 22, 2016.
The shareholder class action complaint alleges that Quorum and certain of its executive officers made a series of false and misleading statements and/or failed to disclose to shareholders during the Class Period that: (i) a number of Quorum’s hospitals were underperforming at the time of the spin-off from CHS; (ii) various other indicators of impairment existed at the time of Quorum’s spin-off from CHS; and (iii) Quorum disregarded and/or failed to advise shareholders of the foregoing issues. The complaint further alleges that, as a result of the foregoing, Quorum’s public statements were materially false and misleading at all relevant times.
On August 10, 2016, Quorum stated its financial and operational results for its first quarter as a publicly traded company. For the quarter ended June 30, 2016, the Company stated a net loss of $245 million, or $(8.63) per share, which it blamed on over $250 million of asset impairment and goodwill charges “regardingthe carryover allocation of goodwill” at the time of the spin-off transaction from CHS. Subsequently, Quorum’s Chief Financial Officer stated that “there were indications of impairment” at the time of the spin-off and thereafter.